Healthcare Services

Lung Cancer Liquid Biopsy Market to Reach $2.42 Billion by 2030 at 16.7% CAGR

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Lung Cancer Liquid Biopsy Market Over The 2026–2030 Period?

The lung cancer liquid biopsy market size has experienced swift growth in recent years. It is predicted to increase from $1.12 billion in 2025 to $1.31 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 17.0%. The past growth in this market can be ascribed to a number of elements, including escalating lung cancer incidence rates, the limitations of tissue biopsy procedures, developments in molecular diagnostics, the availability of circulating biomarker technologies, and the expansion of oncology research endeavors.

The lung cancer liquid biopsy market size is projected to experience rapid growth in the upcoming years, with estimations indicating it will expand to $2.42 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.7%. This expansion during the forecast period is primarily driven by the escalating demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, the increasing adoption of companion diagnostics, the expanding integration of AI-driven data analysis, and a heightened focus on early cancer screening programs. Additionally, significant trends expected in the forecast period include a rising adoption of non-invasive diagnostic techniques, an increased utilization of NGS-based liquid biopsy tests, a growing demand for early cancer detection, the widening scope of personalized oncology diagnostics, and enhanced integration of bioinformatics platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Which Key Drivers Are Affecting The Lung Cancer Liquid Biopsy Market Development?

The rising occurrence of lung cancer is anticipated to fuel the expansion of the lung cancer liquid biopsy market in the foreseeable future. Lung cancer defines a condition marked by the unchecked proliferation of atypical cells within the lungs, frequently stemming from smoking and environmental factors. Its prevalence is growing primarily because of persistent tobacco consumption, where smoking introduces carcinogens to the lungs, stimulating irregular cellular development. Lung cancer liquid biopsy offers assistance through the identification of cancer-associated genetic mutations and tumor DNA from blood specimens, facilitating prompt diagnosis, appropriate treatment selection, and continuous observation of disease advancement or therapeutic response. For example, in January 2023, data from a report issued by the American Cancer Society (ACS), a U.S.-based nonprofit organization, projected that in 2023, an estimated 238,340 individuals, comprising 117,550 men and 120,790 women, would receive a lung cancer diagnosis, with 127,070 people anticipated to succumb to the illness. Consequently, the rising incidence of lung cancer is a key factor propelling the expansion of the lung cancer liquid biopsy market.

What Are The Main Segments Within The Lung Cancer Liquid Biopsy Market Segment Structure?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

What Trends Are Transforming The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are emphasizing the development of technological advancements, such as blood-based lung cancer screening tests, to boost early detection capabilities, refine diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test employs a non-invasive method to analyze biomarkers in the bloodstream, identifying lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, launched FirstLook Lung, a blood-based liquid biopsy test designed to assist in early lung cancer detection. This test utilizes fragmentomics to detect early lung cancer with high sensitivity and a 99.8% negative predictive value, making it an accessible and convenient initial step for at-risk individuals. Its purpose is to enhance early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Who Are The Companies Participating In The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Get The Full Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Region Accounts For The Largest Portion Of The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lung Cancer Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795